SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-22-000175
Filing Date
2022-02-10
Accepted
2022-02-10 08:10:23
Documents
13
Period of Report
2022-02-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ALNYLAM PHARMACEUTICALS, INC. 8-K a52572231.htm   iXBRL 8-K 25060
2 EXHIBIT 99.1 a52572231ex99_1.htm EX-99.1 410200
  Complete submission text file 0001157523-22-000175.txt   601966

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alny-20220210.xsd EX-101.SCH 3920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20220210_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20220210_pre.xml EX-101.PRE 16040
7 EXTRACTED XBRL INSTANCE DOCUMENT a52572231_htm.xml XML 4253
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 22609656
SIC: 2834 Pharmaceutical Preparations